Watson challenges Azilect patent; Roche says it's 'on track' to meet growth goals;

 @FiercePharma: Takeda rep sues for overtime pay. Article | Follow @FiercePharma

Special Report: The 2010 Biotech Graveyard. Report

> Watson Laboratories has filed an ANDA seeking approval to market rasagiline mesylate 0.5 and 1.0 mg tablets. Watson's rasagiline mesylate tablets are generic versions of Teva Neuroscience, Inc.'s Azilect tablets, which are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease as initial monotherapy and as adjunct therapy to levodopa. Watson release

> Roche Holding AG is on track to meet its full-year growth goals, the drugmaker said in slides prepared for a presentation on Tuesday, just over a week ahead of publication of its third-quarter sales figures. Article

> Par Pharmaceutical's licensing partner, Tris Pharma, has received final FDA approval for its ANDA for hydrocodone polistirex and chlorpheniramine polistirex (CIII) extended-release oral suspension.  Hydrocodone polistirex and chlorpheniramine polistirex (CIII) ER oral suspension is a generic version of UCB's Tussionex, which is used for relief of cough and upper respiratory symptoms associated with allergy or a cold. Par release

> Abbott Labs alleged persuaded Medicaid to pay $3.3 million for freezer pops by pretending they were drugs approved by the FDA, according to a whistleblower lawsuit that illustrates how stricter government oversight could prevent drug companies from defrauding taxpayers. Story

> Pfizer Consumer Healthcare on Monday launched a consumer campaign encouraging Americans to clean out their medicine cabinets and properly dispose of unwanted, expired and recalled products. News

> Chronic kidney disease (CKD) patients with hyperposphataemia will now have access to a new treatment option in the UK following the launch of Genzyme's Renvela this week. Report

> Sihuan Pharmaceutical, a cardiovascular drug company in China, is searching for up to $700 million in funding for its first public offering on the Hong Kong market, scheduled for the end of this month. The company was previously traded on the Singapore market. Story

Biotech News

 @FierceBiotech: Cancer researchers testing radical change in drug trials. Article | Follow @FierceBiotech

 @JohnCFierce: Langer starts biotech companies more often than I buy boots. And I have a closet full. |  Follow @JohnCFierce

> GSK bets hungry spinouts can upstage fat pharma. Story

> Novartis takes $590M hit as HGS ditches hep C drug Zalbin. Item

> Pacific BioSciences boosts target as it files $230M IPO. Report

> WSJ: What's the next Big Biotech on pharma's shopping list?. Article

Biotech Research News

> Florida Keys home to potential colon cancer fighter. News

> IOM report seeks to ramp up R&D war against rare diseases. Report

> Pieris forges discovery pact with Sanofi-Aventis. Story

> Biotech in the Big Easy. Report

Manufacturing News

> Disposables/stainless compatibility standard needed. Story

> Virtual model threatens drug lifecycle expertise. Item

> With impetus from Congress, J&J investors stir. Report

> Brazil to join ranks of Gaucher's drug makers. News

> Traditional Chinese drugmakers prep to invade the West. Article

> Shanghai Roche announces Avastin OK in China. News

And Finally... Some newspapers are finding new sources of revenue, namely ads for medical marijuana. It's a win-win situation; papers stay afloat during a trying time in their history, and fledgling cannibis businesses can tout their newly legalized businesses. Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.